Amgen Inc. (AMGN) fair value analysis

S&P 500 & Nasdaq · Updated 2026-09-07

Amgen Inc. is a multinational biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics with a focus on oncology, cardiovascular disease, inflammation, and bone health. The company operates globally with research, manufacturing, and distribution facilities across multiple continents serving patients in numerous countries worldwide.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, AMGN is trading at more than a 25% premium to estimated fair value.

AMGN currently ranks #105 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $437.23
Sector: Healthcare
12-month range: $294.20–$438.12

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: High
Margin trend: Stable
Revenue growth: Strong
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range
DCF cross-check: Undervalued

What our data shows for AMGN

Our model validated 17 trailing price-to-earnings windows for AMGN, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $294.20–$438.12.
The 14-day relative strength index sits at a neutral 62.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for AMGN
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent AMGN news

TickrTrends' derived news-sentiment signal for AMGN is currently mixed, computed from recent coverage.

Lilly perseveres in a bad day for drug stocks — plus, Boeing's mixed deliveries (cnbc.com, 2026-09-08)
TickrTrends take: Amgen operates in the Healthcare sector alongside competitors like Lilly, and broader pressure on drug stocks could test whether Amgen's current valuation premium is justified by its pipeline and commercial performance. TickrTrends' overvalued assessment suggests the market may be pricing in optimistic expectations that sector headwinds could challenge. Investors focused on valuation should monitor whether weakness among peer companies signals deteriorating fundamentals in the pharmaceutical space or presents a repricing opportunity.
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party? (finance.yahoo.com, 2026-09-07)
TickrTrends take: The Biotechnology ETF's outperformance suggests investor appetite for healthcare innovation, though AMGN's current overvalued status according to TickrTrends indicates the sector's gains may not extend uniformly across all holdings. A valuation-focused reader should monitor whether AMGN can justify its current pricing through earnings growth or if sector momentum is masking fundamental concerns at the individual stock level. The divergence between broad biotech strength and AMGN's valuation assessment presents a key tension worth tracking as the market reassesses healthcare positions.

What people are saying

Follow the AMGN conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — # AMGN Weekly Indicator Summary TickrTrends' derived indicators for AMGN showed a significant shift this week, with the DCF cross-check band moving from an overvalued assessment to an undervalued position. Despite this improvement in the DCF metric, the current overall valuation verdict remains overvalued for the healthcare sector company. This divergence between the DCF indicator and the broader valuation assessment suggests mixed signals in AMGN's fundamental valuation metrics.
2026-09-06 — AMGN's valuation assessment shifted this week from overvalued to overvalued, with the DCF cross-check band moving from undervalued to overvalued. The stock's momentum rating declined from C to none, indicating a weakening in price trend strength. These changes suggest reduced upward price pressure alongside the company's current overvalued positioning within the Healthcare sector.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is AMGN stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), AMGN is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is AMGN's TickrTrends verdict?

AMGN's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does AMGN compare to other Healthcare stocks?

AMGN ranks #105 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is AMGN overbought or oversold?

AMGN's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

AMGN vs ACAD · AMGN vs ALKS · AMGN vs BMY · AMGN vs CDNA · AMGN vs DGX